The objective of this study is to evaluate the safety and efficacy of priming vaccinations, and subsequent boosting vaccinations with Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines (Allogeneic Prostate GVAX®). Clinical observations and laboratory measurements will be monitored to evaluate safety and toxicity. Additionally, the antitumor effects of Allogeneic Prostate GVAX® on serum PSA levels will be evaluated and antitumor responses will be quantitated.

Inclusion Criteria:

• Diagnosis of adenocarcinoma prostate cancer
• No evidence of measurable metastatic disease
• An ECOG performance status of 0 or 1

Exclusion Criteria:

• Previous hormonal therapy of any type for prostate cancer
• Any previous chemotherapy, or prior investigational therapy for prostate cancer
• Prior Immunotherapy
• Prior treatment with gene therapy